Grupo de Investigación en Cáncer de Mama
NEONCOBREAST
Stanford University School of Medicine
Stanford, Estados UnidosPublications in collaboration with researchers from Stanford University School of Medicine (1)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268